Richard is an NCI fellowship-trained medical oncologist with extensive experience in clinical trials in oncology and radiologic imaging. He served as Deputy Associate Director of the NCI Developmental Therapeutics Program (DTP) managing the division’s personnel, natural products group, biological and pharmaceutical laboratories at Ft. Detrick, MD, as well as being an attending physician for DTP Phase I clinical trials. After government service, Richard was an academic oncologist at Michigan State University, heading the breast cancer team as Principal Investigator for several National Surgical Adjuvant Breast and Bowel Project (NSABP) cooperative group trials. His pharmaceutical and biotech experience includes being a clinical research physician at Eli Lilly and Company and serving as Vice President for Medical Affairs at Endocyte, Inc. where his leadership supported a successful IPO for the company (Feb 2011) and a $1B licensing partnership with Merck (March 2012).

Source: Apexian Pharmaceuticals, Inc. on 11/26/2020